|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
64,920,000 |
Market
Cap: |
978.34(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$13.43 - $23.54 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 31.4 |
Insider 3/6 Months : 32 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer therapies. Co.'s products include: Domvanalimab, which is an anti-TIGIT monoclonal antibody designed to promote sustained immune activation and tumor clearance; Etrumadenant, which is a dual A2a/A2b adenosine receptor antagonist, designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells; AB680, which is a potent and selective small-molecule CD73 inhibitor designed to provide differential benefits relative to monoclonal antibodies; and Zimberelimab, which is Co.'s anti-PD-1 antibody that Co. in-licensed to enable the development of its combination regimens.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
15,238,095 |
16,248,095 |
16,248,095 |
Total Buy Value |
$0 |
$319,999,995 |
$339,452,595 |
$339,452,595 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
2 |
2 |
Total Shares Sold |
25,000 |
141,157 |
237,875 |
329,459 |
Total Sell Value |
$443,661 |
$2,727,236 |
$4,652,676 |
$7,003,905 |
Total People Sold |
1 |
3 |
4 |
6 |
Total Sell Transactions |
2 |
9 |
16 |
33 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Jarrett Jennifer |
Chief Operating Officer |
|
2024-03-27 |
4 |
AS |
$17.55 |
$202,720 |
D/D |
(11,551) |
215,253 |
|
-17% |
|
Jarrett Jennifer |
Chief Operating Officer |
|
2024-03-18 |
4 |
S |
$17.84 |
$240,941 |
D/D |
(13,449) |
226,804 |
|
13% |
|
Jarrett Jennifer |
Chief Operating Officer |
|
2024-02-27 |
4 |
AS |
$20.11 |
$685,148 |
D/D |
(34,070) |
240,253 |
|
-25% |
|
Jaen Juan C. |
President |
|
2024-02-27 |
4 |
AS |
$20.10 |
$464,953 |
I/I |
(23,132) |
1,188,233 |
|
-25% |
|
Jarrett Jennifer |
Chief Operating Officer |
|
2024-02-26 |
4 |
AS |
$20.07 |
$492,819 |
D/D |
(24,555) |
274,323 |
|
-23% |
|
Jaen Juan C. |
President |
|
2024-02-26 |
4 |
AS |
$20.06 |
$78,234 |
I/I |
(3,900) |
1,211,365 |
|
-23% |
|
Gilead Sciences Inc |
10% Owner |
|
2024-01-29 |
4 |
B |
$21.00 |
$319,999,995 |
D/D |
15,238,095 |
30,061,124 |
2.45 |
-2% |
|
Goeltz Ii Robert C. |
Chief Financial Officer |
|
2024-01-23 |
4/A |
A |
$0.00 |
$0 |
D/D |
22,000 |
73,831 |
|
- |
|
Jarrett Jennifer |
Chief Operating Officer |
|
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
298,878 |
|
- |
|
Jaen Juan C. |
President |
|
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
341,475 |
|
- |
|
Nuyten Dimitry Sa |
Chief Medical Officer |
|
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
99,195 |
|
- |
|
Rosen Terry J |
Chief Executive Officer |
|
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
3,966,974 |
|
- |
|
Tang Carolyn C. |
General Counsel |
|
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
26,700 |
114,579 |
|
- |
|
Azoy Alexander |
Chief Accounting Officer |
|
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
8,850 |
19,070 |
|
- |
|
Goeltz Ii Robert C. |
Chief Financial Officer |
|
2024-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
21,300 |
73,131 |
|
- |
|
Goeltz Ii Robert C. |
Chief Financial Officer |
|
2024-01-02 |
4 |
AS |
$20.00 |
$40,080 |
D/D |
(2,004) |
51,831 |
|
-13% |
|
Jaen Juan C. |
President |
|
2024-01-02 |
4 |
AS |
$20.09 |
$140,128 |
I/I |
(6,975) |
1,215,265 |
|
-13% |
|
Rosen Terry J |
Chief Executive Officer |
|
2023-12-29 |
4 |
A |
$0.00 |
$0 |
D/D |
448 |
3,866,974 |
|
- |
|
Jarrett Jennifer |
Chief Operating Officer |
|
2023-12-22 |
4 |
AS |
$17.76 |
$382,213 |
D/D |
(21,521) |
258,878 |
|
-12% |
|
Azoy Alexander |
Chief Accounting Officer |
|
2023-12-20 |
4 |
D |
$18.21 |
$1,238 |
D/D |
(68) |
10,220 |
|
- |
|
Jaen Juan C. |
President |
|
2023-12-19 |
4 |
D |
$18.09 |
$113,225 |
D/D |
(6,259) |
301,475 |
|
- |
|
Azoy Alexander |
Chief Accounting Officer |
|
2023-12-19 |
4 |
D |
$18.09 |
$11,957 |
D/D |
(661) |
10,288 |
|
- |
|
Nuyten Dimitry Sa |
Chief Medical Officer |
|
2023-12-19 |
4 |
D |
$18.09 |
$27,859 |
D/D |
(1,540) |
71,195 |
|
- |
|
Tang Carolyn C. |
General Counsel |
|
2023-12-19 |
4 |
D |
$18.09 |
$73,735 |
D/D |
(4,076) |
87,879 |
|
- |
|
Goeltz Ii Robert C. |
Chief Financial Officer |
|
2023-12-19 |
4 |
D |
$18.09 |
$50,797 |
D/D |
(2,808) |
53,835 |
|
- |
|
207 Records found
|
|
Page 1 of 9 |
|
|